Palvella Therapeutics - Public Comps and Valuation Multiples

Palvella Therapeutics Overview

About Palvella Therapeutics

Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company’s lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company’s patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

Founded

2015

HQ

Employees

Website

palvellatx.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

Last FY Revenue n/a

LTM EBITDA -$30.1M

EV

$534M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Palvella Therapeutics Financials

As of August 2025, Palvella Therapeutics reported last 12-month EBITDA of -$30.1M.

In the same period, Palvella Therapeutics achieved -$31.3M in LTM net income.

See Palvella Therapeutics valuation multiples based on analyst estimates

Palvella Therapeutics P&L

In the most recent fiscal year, Palvella Therapeutics reported EBITDA of -$13.1M.

Palvella Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Palvella Therapeutics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	n/a	XXX	n/a	XXX	XXX	XXX
Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
Gross Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA	-$30.1M	XXX	-$13.1M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBIT	-$30.4M	XXX	-$14.1M	XXX	XXX	XXX
EBIT Margin	n/a	XXX	n/a	XXX	XXX	XXX
Net Profit	-$31.3M	XXX	-$17.4M	XXX	XXX	XXX
Net Margin	n/a	XXX	n/a	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Palvella Therapeutics including revenue, profitability, and margin analysis across different time periods. EBITDA for the last twelve months was -$30.1M.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$30.1M	Analyst estimates available to subscribers	-$13.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$30.4M	Analyst estimates available to subscribers	-$14.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$31.3M	Analyst estimates available to subscribers	-$17.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Palvella Therapeutics

This financial data table provides comprehensive performance metrics for Palvella Therapeutics, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

The company achieved -$30.1M in EBITDA over the last twelve months.
Net income over the last twelve months reached -$31.3M.

Fiscal Year Performance

Fiscal year EBITDA was -$13.1M.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Palvella Therapeutics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Palvella Therapeutics Stock Performance

Palvella Therapeutics has current market cap of $604M, and EV of $534M.

Market Cap Evolution

Palvella Therapeutics Stock Data

As of September 16, 2025, Palvella Therapeutics's stock price is $55.

See Palvella Therapeutics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$534M	$604M	XXX	XXX	XXX	XXX	$-4.55

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Palvella Therapeutics Valuation Multiples

Palvella Therapeutics's trades at n/a EV/Revenue multiple, and -40.7x EV/EBITDA.

See valuation multiples for Palvella Therapeutics and 15K+ public comps

Palvella Therapeutics Financial Valuation Multiples

As of September 16, 2025, Palvella Therapeutics has market cap of $604M and EV of $534M.

Equity research analysts estimate Palvella Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Palvella Therapeutics has a P/E ratio of -19.3x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$604M	XXX	$604M	XXX	XXX	XXX
EV (current)	$534M	XXX	$534M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	n/a	XXX	XXX	XXX
EV/EBITDA	-17.8x	XXX	-40.7x	XXX	XXX	XXX
EV/EBIT	-17.6x	XXX	-37.9x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	-19.3x	XXX	-34.7x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-49.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Palvella Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Palvella Therapeutics Margins & Growth Rates

Palvella Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.0M for the same period.

Palvella Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Palvella Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Palvella Therapeutics and other 15K+ public comps

Palvella Therapeutics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	49%	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.0M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial